Leinco Technologies

Recombinant Mouse RANK Ligand

Product Code:
 
LEI-R1134
Product Group:
 
Recombinant Proteins
Host Type:
 
Mouse
Regulatory Status:
 
RUO
Shipping:
 
Ambient
Storage:
 
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-R1134-10ug10 ug£614.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Format:
This recombinant protein was lyophilized from a 0.2 um filtered solution in 20 mM sodium phosphate (NaH2PO4), 200 mM NaCl, and 0.1 mM EDTA, pH 7.0.
Formulation:
This recombinant protein was lyophilized from a 0.2 um filtered solution in 20 mM sodium phosphate (NaH2PO4), 200 mM NaCl, and 0.1 mM EDTA, pH 7.0.
Long Description:
RANKL (Receptor Activator for Nuclear Factor κ B Ligand), also known as TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and ODF (osteoclast differentiation factor), is a member of the tumor necrosis factor family cytokine.1 RANKL is essential for osteoclast formation, activation, and survival.2 RANKL through interaction with its receptor RANK can modulate matrix degradation and inflammation.3 RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy. Consequently, novel drugs specifically targeting RANK, RANKL, and their signaling pathways in osteoclasts are expected to revolutionize the treatment of various ailments associated with bone loss, such as arthritis, periodontal disease, cancer metastases, and osteoporosis.4
Purity:
>95% by SDS-PAGE and analyzed by silver stain.
Target:
RANKL

References

1. Takayanagi, H. et al. (2003) Arthritis Res Ther. 5: 202. Kostenuik, PJ. et al. (2005) Endocrinology 146: 32353. Holven ,KB. et al. (2009) Stroke 40: 2414. Penninger, JM. et al. (2008) Ann N Y Acad Sci. 1143: 123